Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib

Inclusion criteria

• ✓. Written consent;
• ✓. A patient who voluntarily provided a written consent form before participating in a clinical trial;
• ✓. A patient who voluntarily provided written consent for genetic research for genetics and/or exploratory research
• ✓. Age and gender
• ✓. Those over 20 years old
• ✓. Female patients should agree to use proper contraception and should not be breastfeeding, and for women of childbearing age, there should be evidence that pregnancy is negative before the start of administration or satisfies one of the following criteria for screening A woman who is over 50 years of age and has amenorrhea for at least 12 months after she stops all foreign hormone treatments Record of irreversible surgical infertility by hysterectomy, bilateral hysterectomy, or bilateral hysterectomy, tubal ligation is not allowed Women under the age of 50 remain in a state of amenorrhea for at least 12 months after stopping all foreign hormone therapy, and their luteinizing hormone (LH) and follicular-stimulating hormone (FSH) levels are within the range of menopause
• ✓. Male patients who have not undergone vasectomy must agree to blocking contraception, that is, the use of condoms, and are prohibited from providing sperm up to three months after the last clinical trial
• ✓. Target disease a) Patients with locally progressive or metastatic non-small cell lung cancer identified histologically or cytologically b) Eastern Oncology Cooperative Group (ECOG) Performance Status 0\~2 c) Patient with at least three months of life expectancy A patient with at least one measurable lesion according to RECIST v1.1 criteria (the area that has received previous local treatment cannot be a target lesion. However, if three months have passed since the previous local treatment and the progression of the lesion is confirmed, it can be regarded as a target lesion.) e) Patients with EGFR mutations identified before administration of Lazertinib (L858R, Exon 19 deletion mutations must be confirmed by record) f) Patients who fail Lazertinib treatment (including all of the following cases)